

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

93728

Licensee

1. Botsford General Hospital
2. 28050 Grand River Avenue
Farmington Hills, MI 48024

In accordance with letter dated
June 30, 1992

3. License number 21-08892-01 is amended in its entirety to read as follows:

4. Expiration date November 30, 1994

5. Docket or
Reference No 030-02077

6. Byproduct, source, and/or
special nuclear material

7. Chemical and/or physical
form

8. Maximum amount that licensee
may possess at any one time
under this license

A. Any byproduct
material identified
in 10 CFR 35.100

A. Any radiopharmaceutical
identified in 10 CFR
35.100

A. As needed

B. Any byproduct
material identified
in 10 CFR 35.200

B. Any radiopharmaceutical
identified in 10 CFR
35.200

B. As needed

C. Any byproduct
material identified
in 10 CFR 35.300

C. Any radiopharmaceutical
identified in 10 CFR
35.300 (excluding
iodine-131 for thyroid
carcinoma)

C. As needed

D. Any byproduct
material identified
in 10 CFR 31.11

D. Prepackaged Kits

D. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).

D. In vitro studies.

9302260042 920819
PDR ADDCK 03002077
C PDR

2 ML
30
DH

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
21-08892-01

Docket or Reference
030-0

Amendment No. 47

CONDITIONS

10. Location of Use: 28050 Grand River Avenue, Farmington Hills, Michigan.
11. Radiation Safety Officer: Stephan Morse, D.O.
12. Authorized Users:
 - Leo Sheiner, D.O., for material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), and 31.11.
 - Stephan Morse, D.O., for material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), and 31.11.
 - Samuel Jassenoff, D.O., for material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), and 31.11.
 - George Leach, D.O., for material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), and 31.11.
 - Andrew Mizzi, D.O., for material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), and 31.11.
 - Irving Haiman, D.O., for material in 10 CFR 35.100, 35.200, and 31.11.
 - David Wiseley, D.O., for material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), and 31.11.
 - Steven J. Zuckerman, D.O., for material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), and 31.11.
 - Robert Jon Wittchow, D.O., for material in 10 CFR 35.100 and 35.200.
 - Anthony R. Pucci, D.O., for material in 10 CFR 35.100 and 35.200.
13. Pursuant to Title 10, Chapter I, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.
14. The licensee shall maintain records of information important to safe and effective decommissioning at the address in Condition 10. per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

21-08892-01

Docket or Reference number

030-02077

Amendment No. 47

15. This license is based on the licensee's statements and representations listed below:

- A. Application dated June 21, 1989.
- B. Letter to inspection staff dated August 30, 1989.
- C. Letter dated October 2, 1989.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 19 1992

By

George H. Feltus
Materials Licensing Section
Region III

COPY

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02120
STATUS CODE: 0
FEE CATEGORY: 7C
EXP. DATE: 19941130
FEE COMMENTS: CODE 23
DECOM FIN ASSUR REQ: N
TT

LICENSE FEE TRANSMITTAL

A. REGION III

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: BOTSFORD GENERAL HOSPITAL
RECEIVED DATE: 920721
DOCKET NO: 3002077
CONTROL NO.: 393728
LICENSE NO.: 21-08892-01
ACTION TYPE: AMENDMENT

2. FEE ATTACHED
AMOUNT: \$430.00
CHECK NO.: 627-282

3. COMMENTS

SIGNED P. Little
DATE 7-22-92

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED ☒)

1. FEE CATEGORY AND AMOUNT: 7C \$430

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT ☒
RENEWAL ☐
LICENSE ☐

3. OTHER

SIGNED
DATE

Rita Jacques
7/24/92

RECEIVED

JUL 30 1992

REGION III

(FOR LFMS USE)
INFORMATION FROM LTS

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

PROGRAM CODE: 02120
STATUS CODE: 0
FEE CATEGORY: 7C
EXP. DATE: 19941130
FEE COMMENTS: CODE 23
DECOM FIN ASSUR REQD: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: BOTSFORD GENERAL HOSPITAL
RECEIVED DATE: 920721
DOCKET NO: 3002077
CONTROL NO.: 393728
LICENSE NO.: 21-08892-01
ACTION TYPE: AMENDMENT

2. FEE ATTACHED
AMOUNT: \$120.00
CHECK NO.: 644250

3. COMMENTS

SIGNED
DATE

P. Lutz
7-22-92

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED / /)

1. FEE CATEGORY AND AMOUNT: _____

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT _____
RENEWAL _____
LICENSE _____

3. OTHER _____

SIGNED
DATE

RECEIVED

JUL 21 1992


REGION III

rpm 7/17/92

An Osteopathic Organization Serving the Community

CONTROL NO.

93728


botsford
general
hospital

28050 Grand River
Farmington Hills, MI 48024
(313) 471-8000
FAX (313) 471-8505

June 30, 1992

United States Nuclear Regulatory Commission
Region III, Medical Licensing Division
799 Roosevelt Road
Glen Ellyn, Illinois 60137

Re: License Amendment

Dear Sir/Madam:


We would like to amend our By-Product Materials License No. 21-08892-01 by adding Anthony Pucci, D.O. to our list of authorized users. Please add him as an authorized user for groups 35.100 and 35.200.

Enclosed is a copy of Dr. Pucci's preceptor statement.

A check is enclosed for the \$430.00 amendment fee.

If you have any questions regarding this amendment request, please contact our consultant, Tracy King, at (313) 662-3197.

Sincerely,



William Scheuber
Administrator
Professional and Support Services

Enclosures (2)

Log *Jul 18 1992*
Remitter
Check No. *044387*
Amount *430*
Fee Category *MC*
Type of Fee *and*
Date Check Rec'd. *7/23*
Date Completed *7/24*
By: *[Signature]*

RECEIVED
U.S. NUCLEAR REGULATORY COMMISSION
JUL 23 1992 3:29 PM

RECEIVED
JUL 21 1992
REGION III

pm 7/17/92

An Osteopathic Organization Serving the Community

CONTROL NO.

JUL 21 1992
93728

Dr. Pucci was previously listed on the By-product Materials License
at Michigan Osteopathic Medical Center, license number 21-03835-01.

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS		KEY TO COLUMN C
FULL NAME <i>Anthony R. P...</i>		PERSONAL PARTICIPATION SHOULD CONSIST OF: 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage. 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data. 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.
STREET ADDRESS <i>26551 W Carnegie Pk Dr.</i>		
CITY <i>Southfield,</i>	STATE <i>MI</i>	
ZIP CODE <i>48034</i>		

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	30	Venograms - 402 Lumbar Shunts - 6 Neph - 40 Schilling - 9 Testicular - 28 Gastric emptying - 20 GI reflux - 15 Fistulogram - 1 Hepatobiliary - 160 GI Bleed scan - 28
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	30	
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Sr-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY	5	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING	12	
	CARDIAC IMAGING	640	
	THYROID IMAGING	140	
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING (mugs)	605	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	230	
	LUNG IMAGING	855	
	BONE IMAGING	405	
OTHER			

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	3	
	TREATMENT OF HYPERTHYROIDISM	4	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELEGRAPHY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mn-59/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

Michigan Health Center - 1987-90 resident - 2080 hours
 Detroit, MI
 July June
 Oakwood Hospital - April-May 89 - 160 hours
 Dearborn, MI

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

b. NAME OF INSTITUTION

c. MAILING ADDRESS

d. CITY

5. PRECEPTOR'S SIGNATURE

7. PRECEPTOR'S NAME (Please type or print)

8. DATE

5. MATERIALS LICENSE NUMBER(S)


ANTHONY PUCCI, D.O.

To Whom it may concern:


The above named individual has successfully completed a Residency Program in Diagnostic Radiology to include six (6) months direct interaction and training in Nuclear Medicine at the following ACGME approved program.

Michigan Health Center
2700 ML King Jr Blvd
Detroit, MI 48208

SIGNED:



Anthony Pucci, D.O.



Frank J. Messana, D.O.
Radiation Safety Officer

6-30-90

CONTROL NO.

93728

AUG 21 1992

Botsford General Hospital
ATTN: Stephan Morse, D.O.
Radiation Safety Officer
28050 Grand River Avenue
Farmington Hills, MI 48024

Dear Mr. Morse:

Enclosed is Amendment No. 47 to your NRC License No. 21-08892-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. You must conduct your program involving radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Possess radioactive material only in the quantity and form indicated in your license.
3. Use radioactive material only for the purpose(s) indicated in your license.
4. Notify NRC in writing of any change in mailing address.
5. Request and obtain appropriate amendment if you plan to change ownership of your organization, change locations of radioactive material, or make any other changes in your facility or program which are contrary to your license conditions or representations made in your license application and any supplemental correspondence with NRC. Any amendment request should be accompanied by the appropriate fee specified in 10 CFR Part 170.
6. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.
7. Request termination of your license if you plan to permanently discontinue activities involving radioactive material prior to your expiration date.

93728

Botsford General Hospital

2

AUG 21 1992

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations in your license application will result in enforcement action against you in accordance with the General Policy and Procedures for NRC Enforcement Actions, 10 CFR Part 2, Appendix C.

If you have any questions or require clarification of any of the above stated information, contact us at (708) 790-5625.

Sincerely,

Deborah A. Piskura
Materials Licensing Section

Enclosure: Amendment No. 47

RIII

DP
Piskura/rr
08/19/92